Abstract
Therapy-related acute promyelocytic leukemia (t-APL) has been reported as a late complication of exposure to radiotherapy and/or chemotherapeutic agents targeting DNA topoisomerase II. We have analyzed in t-APL novel gene mutations recently associated with myeloid disorders. Unlike previous reports in acute myeloid leukemia (AML), our results showed neither IDHs nor TET2 mutations in t-APL. However we found an R882H mutation in the DNMT3A gene in a patient with t-APL suggesting a possible role of this alteration in the pathogenesis of t-APL.
Copyright © 2011 Elsevier Ltd. All rights reserved.
Publication types
-
Comparative Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Aged
-
Antineoplastic Agents / adverse effects
-
Child
-
DNA (Cytosine-5-)-Methyltransferases / genetics
-
DNA Methyltransferase 3A
-
DNA Mutational Analysis
-
DNA-Binding Proteins / genetics
-
Dioxygenases
-
Female
-
Humans
-
Isocitrate Dehydrogenase / genetics
-
Leukemia, Promyelocytic, Acute / etiology*
-
Leukemia, Promyelocytic, Acute / genetics*
-
Male
-
Middle Aged
-
Proto-Oncogene Proteins / genetics
-
Radiotherapy / adverse effects
-
Young Adult
-
fms-Like Tyrosine Kinase 3 / genetics
Substances
-
Antineoplastic Agents
-
DNA-Binding Proteins
-
DNMT3A protein, human
-
Proto-Oncogene Proteins
-
IDH2 protein, human
-
Isocitrate Dehydrogenase
-
IDH1 protein, human
-
Dioxygenases
-
TET2 protein, human
-
DNA (Cytosine-5-)-Methyltransferases
-
DNA Methyltransferase 3A
-
FLT3 protein, human
-
fms-Like Tyrosine Kinase 3